Calidi Biotherapeutics Announces New U.S. Patent for SuperNova Technology

In a recent announcement, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a company at the clinical stage of biotechnological development, revealed the issuance of a new patent for its innovative SuperNova technology. This development fortifies Calidi’s intellectual property portfolio and sets the stage for advancing its CLD-201 program into clinical trials.

The United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 12,036,278, titled “Smallpox Vaccine for Cancer Treatment.” This patent is specific to Calidi’s SuperNova platform, which employs adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus. The issuance of this patent marks a significant milestone for the company as it prepares to move the CLD-201 program into clinical settings. Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, expressed satisfaction with this achievement, emphasizing the robust intellectual property portfolio and the promising potential of the SuperNova platform to transform treatment options for patients with advanced solid tumors.

The patent encompasses methods and compositions related to cancer immunotherapy, particularly those combining a smallpox vaccine with stem cells derived from 19 different types. Additionally, it broadens the scope of previously allowed claims to include 21 smallpox vaccine virus strains. Extensive research by Calidi has demonstrated the SuperNova platform’s ability to shield the viral payload from the immune system, ensuring efficient delivery to tumor sites and enhancing the therapeutic efficacy of oncolytic viruses.

Dr. Boris Minev, President of Medical and Scientific Affairs at Calidi Biotherapeutics and a patent inventor, highlighted the vast potential of the SuperNova technology to meet the significant unmet need for effective solid tumor treatments. Building on the initial clinical successes of autologous adipose-derived stem cells loaded with vaccinia oncolytic viruses, Calidi plans to submit an Investigational New Drug (IND) application. This submission aims to initiate the first-in-human clinical trial of the off-the-shelf allogeneic therapy. Calidi continues to deepen its understanding of the safety and effectiveness of CLD-201 in treating patients with advanced solid tumors.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company headquartered in San Diego, California. The company’s novel stem cell-based platforms are designed to arm the immune system to fight cancer. Utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses, Calidi targets various oncology indications, including high-grade gliomas and solid tumors. The off-the-shelf, universal cell-based delivery platforms aim to protect, amplify, and potentiate oncolytic viruses, thereby enhancing efficacy and improving patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are tailored to target disseminated solid tumors, with a dual approach that has the potential to treat or even prevent metastatic disease.